ClinicalTrials.gg
CompletedNCT07317063Updated Feb 13, 2026

A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants

A Phase 1 interventional study of GRT6019 in Duchenne Muscular Dystrophy (DMD), sponsored by Grünenthal GmbH. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
107th of 171
18 · median 25
Started
2025
with 9 others
Phase 1
32 of 232
3 open now
Registered
225th of 232
by date

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 107th largest by enrollment of the 171 interventional ones that give a count, is one of 10 that started in 2025, is one of 32 in phase 1, and was the 225th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the safety, tolerability, and Pharmacokinetics (PK) of a single oral dose of GRT6019 in healthy male participants, including food effect.

This is an open-label, single-dose, single-center Phase I trial with healthy male participants. The trial will consist of 2 cohorts with a total duration of approximately 7 weeks, including a 28-day Screening Period.

The participants will receive a single dose of GRT6019 administered on Day 1 and will remain at the clinic for 7 additional days.

Following the in-house stay, there will be 2 Follow-up Visits up until Day 23, with 3 clinic visits scheduled

Read the detailed description

Cohort 1 and Cohort 2 will be dosed in parallel:

  • Cohort 1 (n = 9): single dose of GRT6019 in participants in a fed state
  • Cohort 2 (n = 9): single dose of GRT6019 in participants in a fasted state
03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Main inclusion Criteria:

  1. The participant must be able to give signed , including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Participants must sign the ICF before any trial-related assessments.
  3. The participant is in good health as determined by the medical history, physical examination, 12-lead (ECG), vital signs (heart rate [HR], respiratory rate [RR], systolic and diastolic blood pressure [BP]), body temperature, and clinical laboratory parameters (clinical chemistry, hematology, coagulation, and urinalysis) without (per investigator judgement) deviations from reference ranges unless further specified in the exclusion criteria.

Main exclusion Criteria:

  1. Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, comparator, rescue medication, or any ingredients therein, or may affect the interpretation of the results, or may render the patient at high risk from treatment complications/ participation in the study unsafe.
  2. Major surgical procedure, within 3 months prior to ICF signing, or anticipation of need for a major surgical procedure during the trial.
  3. Clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, or immunological disorder(s) as determined by the investigator.
  4. Any medication, including herbal remedies or over-the-counter medication within 2 weeks before screening into this trial and anticipated use during the trial.
  5. Concurrent enrollment in another clinical trial unless it is an observational (non-interventional) clinical trial or during the Follow-up Period of an interventional trial.
  6. Recent participation in another clinical trial with an IMP administered within 30 days before Day 1 OR within 5 times the elimination half-life of the IMP, whichever is longer.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    GRT6019 :Cohort 1

    Fed State

    Drug: GRT6019

  • Experimental
    GRT6019: Cohort 2

    Fasted State

    Drug: GRT6019

Interventions

  • Single Dose

    Also known as: Study drug

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events

    Assessment of safety and tolerability of GRT6019 after a single oral dose

    Time frame: Through study completion, an average of 7 Weeks

  2. Number of participants with serious Adverse Events

    Assessment of safety and tolerability of GRT6019 after a single oral dose

    Time frame: Through study completion, an average of 7 Weeks

  3. Number of participants with Adverse Events leading to discontinuation

    Assessment of safety and tolerability of GRT6019 after a single oral dose

    Time frame: Through study completion, an average of 7 Weeks

  4. Number of participants with Adverse Events related with GRT6019

    Assessment of safety and tolerability of GRT6019 after a single oral dose

    Time frame: Through study completion, an average of 7 Weeks

Secondary outcomes

  1. Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUC0-t)

    The total amount of the study drug in the blood from the time it is taken until the last time a measurable level of the drug is found. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  2. Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time (AUC0-inf )

    The total amount of the study drug in the blood from the time it is taken until it has completely left the body. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  3. Maximum plasma concentration (Cmax)

    The maximum amount of the study drug measured in the blood after taking the dose. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  4. Time of maximum plasma concentration (Tmax)

    The time it takes to reach the highest concentration of the study drug in the blood after dosing. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  5. Lag-time observed from dosing to the time point prior to that of the first quantifiable plasma concentration (Tlag). Assessment of the PK of GRT6019 following a single oral dose of the pediatric formulation under fasted and fed conditions.

    The time between when the study drug is taken and when it first becomes measurable in the blood. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  6. Terminal elimination half life (T₁/₂)

    The time it takes for the amount of study drug in the blood to reduce by half after reaching its peak level. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  7. Total body oral clearance (CL/F)

    The amount of blood completely cleared of thestudy drug (and metabolite) per unit of time, taking into account how much of the drug is absorbed into the body. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  8. Apparent volume of distribution (V/F)

    An estimate of how widely the study drug spreads through the body's tissues after it is absorbed. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  9. Ratio of the geometric mean of AUC0-t

    Assessment of the effect of food (fed and fasted state) on the PK of GRT6019 following a single dose.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  10. Ratio of the geometric mean of AUC0-inf

    Assessment of the effect of food (fed and fasted state) on the PK of GRT6019 following a single dose.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

  11. Ratio of the geometric mean of Cmax

    Assessment of the effect of food (fed and fasted state) on the PK of GRT6019 following a single dose.

    Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.

07

Study locations

1 site
  • Biotrial, Inc
    Newark, New Jersey 07103, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jan 2026, 1 month.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 5, 2026
StartActual
Nov 21, 2025
Primary completionActual
Jan 6, 2026
CompletionActual
Jan 6, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07317063
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Nov 21, 2025
Primary completion
Jan 6, 2026
Completion
Jan 6, 2026
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegacorat

Start the discussion